PetMed Express, Inc. names Sandra Campos as new Chief Executive Officer and President

PetMed Express, Inc. announced that the Board of Directors has appointed veteran retail executive and current PetMeds board member Sandra Campos as President and CEO, effective immediately. Ms. Campos also remains on the Board of Directors. Matt Hulett has stepped down as Chief Executive Officer and President and as a Director of the Company and will work with Ms. Campos to facilitate a smooth transition of leadership responsibilities before departing the Company on May 10, 2024. He will remain an advisor to the Company through August 2024.

Campos, a globally recognized, seasoned executive in consumer retail with over 25 years of leadership, previously served as CEO of Diane von Furstenberg and President of a portfolio of global brands including Juicy Couture, BCBG, Bebe and Herve Leger. Ms. Campos’ focus on the ever-evolving consumer landscape has transformed businesses for growth across digital and physical retail through technology, innovative marketing direct to the consumer, and supply chain diversification.

“Sandra is ideally suited to lead PetMeds’ next chapter and the Board is confident in her ability to drive sustainable profitable growth and shareholder value,” said Leslie C. G. Campbell, Chairman of the Board. “She is a proven leader and innovative marketer with a strategic, customer-centric mindset and passion for the pet wellness industry. Her extensive experience in building brands, evolving technology platforms, and driving digital transformations, along with a strong track record of operational excellence, will be instrumental in shaping our future success.”

Speaking on the new role, Ms. Campos said, “I am honored to be joining the PetMeds team as President and CEO and bringing my deep-rooted experience and unwavering passion for the industry to PetMeds at this pivotal time. Based on my background, industry knowledge and understanding of the Company, I am confident that this transition will unfold seamlessly, benefitting all stakeholders of PetMeds.” Campos continued, “In partnership with this dedicated Board, we will continue to focus on harnessing the collective potential of both the PetMeds and PetCareRx teams to propel growth, foster exceptional experiences for our customers and employees and drive significant value for our shareholders. I look forward to talking with analysts and shareholders after our earnings call next month,” Campos concluded.